Marshall Wace’s Mereo BioPharma MREO Stock Holding History

Marshall Wace’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.6K	Sell	179,884 -507,103	-74%	-$152K	﹤0.01%	2982
2026 Q1	$227K	Buy	+686,987	New	+$295K	﹤0.01%	2736
2025 Q4	–	Sell	-767,744	Closed	-$1.58M	–	3275
2025 Q3	$1.58M	Hold	767,744	–	–	﹤0.01%	1724
2025 Q2	$2.08M	Hold	767,744	–	–	﹤0.01%	1545
2025 Q1	$1.73M	Sell	767,744 -98,573	-11%	-$279K	﹤0.01%	1532
2024 Q4	$3.03M	Sell	866,317 -162,195	-16%	-$637K	﹤0.01%	1282
2024 Q3	$4.23M	Sell	1,028,512 -115,539	-10%	-$478K	0.01%	1061
2024 Q2	$4.12M	Buy	+1,144,051	New	+$3.71M	0.01%	1085
2024 Q1	–	Sell	-14,883	Closed	-$34.4K	–	2679
2023 Q4	$34.4K	Buy	+14,883	New	+$28.5K	﹤0.01%	2090
2022 Q1	–	Sell	-98,288	Closed	-$157K	–	3760
2021 Q4	$157K	Buy	+98,288	New	+$197K	﹤0.01%	3245
2021 Q3	–	Sell	-44,682	Closed	-$142K	–	3273
2021 Q2	$142K	Sell	44,682 -28,876	-39%	-$96.9K	﹤0.01%	2501
2021 Q1	$248K	Buy	+73,558	New	+$260K	﹤0.01%	2191

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Marshall Wace's MREO Position: Q2 2026 in Review

Marshall Wace reduced its Mereo BioPharma (MREO) stake by 74% in Q2 2026, selling an estimated $152K and leaving 179,884 shares worth $57.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2982.

Marshall Wace first reported a position in MREO in Q1 2021 and has held it in 12 quarters since. The position peaked at $4.23M in Q3 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Marshall Wace held 179,884 shares of Mereo BioPharma worth $57.6K as of Q2 2026.
Marshall Wace sold 507,103 Mereo BioPharma shares in Q2 2026, an estimated $152K.
Mereo BioPharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2982 holding.
Marshall Wace first reported a position in Mereo BioPharma in Q1 2021 and has held it in 12 quarters since.
Marshall Wace's Mereo BioPharma position peaked at $4.23M in Q3 2024.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.